This is a phase 3 open label, multi-center, randomized, active-controlled non-inferiority trial that compares the safety and effectiveness of a 6-week regimen of daily rifapentine against the current standard of 12-16 weeks of rifamycin-based treatment for latent TB infection (LTBI).
The George Washington University is seeking volunteers for a LTBI clinical trial who are:
- 18 years and older and living in the DC metro area
- Require treatment of LTBI and are at increased risk of progression to tuberculosis
More information regarding the study can be found at clinicaltrials.gov.
Sponsor(s)
The Centers for Disease Control and Prevention (CDC),
Tuberculosis Trials Consortium (TBTC)
Principal Investigator(s)
Dr. Afsoon Roberts,
Dr. Jose Lucar
Contact Phone Number
Request Information